Literature DB >> 3185917

Scales for rating impairment in multiple sclerosis: a critique.

E W Willoughby1, D W Paty.   

Abstract

We reviewed scales proposed over the past 35 years for the rating of neurologic impairment in MS. We focused on the Expanded Disability Status Scale (EDSS) which has been recommended as the most useful scale for rating impairment by the International Federation of Multiple Sclerosis Societies in its Minimal Record of Disability for Multiple Sclerosis. We consider that the EDSS has important flaws that seriously limit its usefulness. In light of the widely accepted three-tier classification of dysfunction developed by the World Health Organization, the title is inappropriate. More substantial problems include inadequate precision in defining the degree of impairment in some functional categories of the scale, and the use of a mixture of neurologic signs elicited on examination and subjective information obtained from the patient in defining the overall scale. We suggest guidelines for developing a "Neurologic Impairment Scale" to rate impairment in MS.

Entities:  

Mesh:

Year:  1988        PMID: 3185917     DOI: 10.1212/wnl.38.11.1793

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  Use of different outcome measures in randomised studies of malignant glioma can significantly alter the interpretation of time to progression: reanalysis of the MRC BR2 study.

Authors:  J Chataway; S Stenning; N Bleehen; R Grant
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

2.  A comparison of responsiveness indices in multiple sclerosis patients.

Authors:  L E Pfennings; H M van der Ploeg; L Cohen; C H Polman
Journal:  Qual Life Res       Date:  1999-09       Impact factor: 4.147

3.  European validation of a standardized clinical description of multiple sclerosis.

Authors:  Maria Pia Amato; Jerome Grimaud; Iuliana Achiti; Maria Letizia Bartolozzi; Patrice Adeleine; Hans-Peter Hartung; Ludwig Kappos; Alan Thompson; Maria Trojano; Sandra Vukusic; Christian Confavreux
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

Review 4.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

5.  Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Authors:  Stuart D Cook; Suhayl Dhib-Jalbut; Peter Dowling; Luca Durelli; Corey Ford; Gavin Giovannoni; June Halper; Colleen Harris; Joseph Herbert; David Li; John A Lincoln; Robert Lisak; Fred D Lublin; Claudia F Lucchinetti; Wayne Moore; Robert T Naismith; Carlos Oehninger; Jack Simon; Maria Pia Sormani
Journal:  Int J MS Care       Date:  2012

6.  A comparison of two neurologic scoring instruments for multiple sclerosis.

Authors:  J A Koziol; A Frutos; J C Sipe; J S Romine; E Beutler
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

7.  Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis.

Authors:  Sara Leddy; Shahrzad Hadavi; Andrew McCarren; Gavin Giovannoni; Ruth Dobson
Journal:  J Neurol       Date:  2013-06-27       Impact factor: 4.849

8.  Problems with rating scales for multiple sclerosis: a novel approach--the CAMBS score.

Authors:  C J Mumford; A Compston
Journal:  J Neurol       Date:  1993       Impact factor: 4.849

9.  A health-related quality of life measure for multiple sclerosis.

Authors:  B G Vickrey; R D Hays; R Harooni; L W Myers; G W Ellison
Journal:  Qual Life Res       Date:  1995-06       Impact factor: 4.147

10.  Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort.

Authors:  Mohammad Ehsanul Karim; Paul Gustafson; John Petkau; Yinshan Zhao; Afsaneh Shirani; Elaine Kingwell; Charity Evans; Mia van der Kop; Joel Oger; Helen Tremlett
Journal:  Am J Epidemiol       Date:  2014-06-17       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.